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o r i g i n a l a r t i c l e
Clostridium difﬁcile Infection Among Veterans Health
Administration Patients
Yinong Young-Xu, ScD, MA, MS;1,2 Jennifer L Kuntz, PhD;3 Dale N. Gerding, MD;4 Julia Neily, RN, MS, MPH;1
Peter Mills, PhD, MS;1,2 Erik R. Dubberke, MD, MSPH;5 Margaret A. Olsen, PhD, MPH;5,6 Ciarán P. Kelly, MD;7
Cédric Mahé, PhD8
objective. To report on the prevalence and incidence of Clostridium difﬁcile infection (CDI) from 2009 to 2013 among Veterans Healthcare
Administration patients
design. A retrospective descriptive analysis of data extracted from a large electronic medical record (EMR) database
setting. Data were acquired from VHA healthcare records from 2009 to 2013 that included outpatient clinical visits, long-term care, and
hospitalized care as well as pharmacy and laboratory information.
results. In 2009, there were 10,207 CDI episodes, and in 2013, there were 12,143 CDI episodes, an increase of 19.0%. The overall CDI rate
increased by 8.4% from 193 episodes per 100,000 patient years in 2009 to 209 episodes per 100,000 patient years in 2013. Of the CDI episodes
identiﬁed in 2009, 58% were identiﬁed during a hospitalization, and 42% were identiﬁed in an outpatient setting. In 2013, 44% of the CDI
episodes were identiﬁed in an outpatient setting.
conclusion. This is one of the largest studies that has utilized timely EMR data to describe the current CDI epidemiology at the VHA. Despite
an aging populationwith greater burden of comorbidity than the general US population, our data show that VHACDI rates stabilized between 2011
and 2013 following increases likely attributable to the introduction of the more sensitive nucleic acid ampliﬁcation tests (NAATs). The ﬁndings in
this report will help establish an accurate benchmark against which both current and future VA CDI prevention initiatives can be measured.
Infect. Control Hosp. Epidemiol. 2015;36(9) :1038–1045
Clostridium difﬁcile is a Gram-positive, anaerobic spore-
forming bacillus that has the potential to infect humans
and cause gastrointestinal disease ranging from acute, watery
diarrhea to severe pseudomembranous colitis, hypotension,
shock, and death.1,2 Symptomatic Clostridium difﬁcile infec-
tions (CDIs) are associated with excess healthcare utilization
including hospitalization and prolonged hospital stay,
increased healthcare costs, and increased risk for adverse out-
comes.3 Recent studies have documented signiﬁcant morbidity
and mortality due to CDI as well as increasing incidence.4,5 As
a result, awareness of the magnitude and the potential threat of
CDI has been growing.
In the Veterans Health Administration (VHA) system,
individual studies focusing on unique aspects of CDI have
been conducted,6,7 but a comprehensive and up-to-date
epidemiological study of CDI for the entire VHA is lacking.
With this report, we aimed to ﬁll that gap by studying CDI in
both inpatient and outpatient settings with data collected
through the VHA electronic medical records (EMR) system.
methods
We conducted a retrospective cohort study among VHA
patients 18 years of age or older between January 1, 2009, and
December 31, 2013.
Description of the VHA Population and Databases
The VHA of the Department of Veterans Affairs (VA) is the
single largest integrated healthcare system in the United States;
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it provides comprehensive services to military veterans. During
our study period, the VHA provided care in 152 hospitals, 135
long-term care facilities (LTCFs), and 820 community-based
outpatient clinics. The VHA has an integrated and uniﬁed
EMR system that contains information about inpatient
and outpatient visits. This data system includes procedures,
surgeries and diagnoses, inpatient and outpatient pharmacy
utilization, laboratory results, extended care, vital signs,
healthcare-related survey data and mortality for all persons
treated within the VHA. Each patient is assigned a unique
identiﬁcation number that allows longitudinal follow-up.
Identiﬁcation of CDI
We identiﬁed CDI episodes from January 1, 2009, through
December 31, 2013, using the following criteria: (1) ICD-9-CM
diagnosis code for CDI (008.45) during an inpatient hospital
stay (discharge diagnosis) or outpatient encounter; (2) positive
test result for C. difﬁcile toxins or toxin genes; or (3) metroni-
dazole or oral vancomycin therapy in the 14 days before or after
a CPT-4 code for a C. difﬁcile test (codes 87230, 87324, 87449,
87803, regardless of result).
To identify only new incident episodes of CDI, we excluded
episodes if the patient had had a CDI in the previous 84 days.8
We used this washout period to minimize misclassiﬁcation
caused by carrying forward the ICD-9-CM diagnosis code for
CDI during subsequent non-CDI clinical encounters.
Date of CDI Onset and Identiﬁcation
The date of onset of CDI was deﬁned as the date corresponding
to the ﬁrst recorded indication of CDI, as described above
(ie, diagnosis, laboratory test, or treatment), unless additional
information was available to deﬁne an earlier date as the date
of onset. If a CDI toxin test was performed, the date of the ﬁrst
positive test was used as the date of CDI onset.
Onset Location and Attribution of CDI
We determined the location of onset and attribution for
each CDI episode using an algorithm based on the most
recent guideline deﬁnitions from the Society for Healthcare
Epidemiology of America (SHEA) and the Infectious Diseases
Society of America (IDSA).9 These categories included
(1) healthcare facility (HCF)-onset, HCF-associated CDI;
(2) community-onset, HCF-associated CDI; (3) community-
associated CDI; and (4) indeterminate. (Expanded deﬁnitions
are included in Appendix A.)
Calculation of CDI Incidence
In any given year, the VHA has ~9 million enrollees, but only
~6 million have an outpatient or inpatient visit. To calculate
the denominator, we counted the number of enrollees who
had any inpatient or outpatient encounter in a single year
because access to VHA patient medical information is con-
tingent upon receipt of healthcare. Multiple outpatient
encounters on the same day were counted as 1 visit. Same-day
transfers within or between hospitals were collapsed to a
single inpatient encounter (while retaining all relevant infor-
mation from the collapsed records) to avoid overcounting
hospitalizations. We compared incidence rates using a Poisson
model. The χ2 test was used to compare proportions and
prevalence; the Mann-Whitney test was used to compare
continuous variables; and the rank-sum test was used to
compare medians. SAS version 9.4 (SAS Institute) was used for
data management and analysis.
Institutional Review Board Approval
Approval from the Dartmouth Institutional Review Board was
obtained to conduct this research.
results
During the study period, the number of patients who had at
least 1 inpatient or outpatient visit to a VHA facility rose from
5,355,424 patients in 2009 to 5,853,358 patients in 2013, and
increase of 9.8% (Table 1). The proportion of VHA patients
aged 65 or older also increased during that time from 41.5% in
2009 to 44.6% in 2013 (P< .0001). The female population
increased from 8.9% to 9.5% (P< .0001), and the percentage
of the total VHA population that was African-American rose
from 12.9% to 14.0% (P< .0001).
The number of patients with ≥1 hospitalization at the
VHA was essentially unchanged over the study time period
(386,786 patients in 2009 vs 386,333 in 2013). The total
number of outpatient visits rose from 63,858,249 visits in
2009 to 75,737,270 in 2013, an increase of 18.6% (Table 1).
Additionally, the median number of outpatient visits per
patient in the outpatient population rose from 6 in 2009 to 7 in
2013 (Table 1, P< .0001).
Trends in Overall CDI Incidence
A total of 10,207 CDI episodes were recorded in 2009.
The number of CDI cases increased through 2012 (12,138 CDI
episodes) and leveled off from 2012 to 2013 (12,143 CDI
episodes) (Figure 1; Table 2). These numbers represent an
increase of 19.0% over the entire study period that was mainly
driven by the 17% increase between 2009 and 2011 (Table 2).
The overall rates of CDI episodes per 100,000 patient years
increased over the study years 2009–2013 by 8.3% (from 193
to 209). The rate stabilized between 2011 and 2012, and
despite the increase in absolute cases of CDI between 2012 and
2013, the CDI rate across the population slightly decreased
(Table 2).
Of the CDI episodes identiﬁed in 2009, 58% (n= 5,955)
were identiﬁed during a hospitalization, while the remaining
42% (n= 4,252) were identiﬁed in the outpatient setting.
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The distribution was relatively similar in 2013 (Table 2). The
rate of hospital onset CDI episodes increased from 6.2 per
10,000 inpatient days in 2009 to 7.4 per 10,000 inpatient days
in 2013, an increase of 20% (P< .0001). In 2009, outpatient
CDI episodes occurred at a rate of 79.4 per 100,000 patients
years, and this rate was 91.7 per 100,000 patient years in 2013,
an increase of 15% (P< .0001, Table 2). From 2010 to 2011,
the incidence of CDI episodes overall increased by 8% (from
table 1. Demographics and Healthcare Utilization in the Veterans Healthcare Administration
Characteristic 2009, No. (%)a 2010, No. (%) 2011, No. (%) 2012, No. (%) 2013, No. (%)
P
Value
Total patients 5,355,424 5,529,234 5,664,328 5,769,237 5,853,358
Age
18–64 y 3,131,610 (58.5) 3,258,336 (58.9) 3,332,525 (58.8) 3,324,763 (57.6) 3,243,134 (55.4)
65 + y 2,223,814 (41.5) 2,270,898 (41.1) 2,331,803 (41.2) 2,444,474 (42.4) 2,610,224 (44.6) <.0001
Gender
Female 473,890 (8.9) 488,889 (8.8) 509,044 (9.0) 536,562 (9.3) 556,567 (9.5)
Male 4,878,453 (91.1) 5,037,129 (91.1) 5,151,947 (91.0) 5,229,262 (90.6) 5,293,212 (90.4)
Unknown 3,081 (0.1) 3,216 (0.1) 3,337 (0.1) 3,413 (0.1) 3,413 (0.1)
Race
White 3,321,786 (62.0) 3,457,756 (62.5) 3,557,119 (62.8) 3,617,378 (62.7) 3,652,416 (62.4)
African-American 689,606 (12.9) 727,260 (13.2) 760,981 (13.4) 792,644 (13.7) 820,809 (14.0)
Hispanic 247,631 (4.6) 261,533 (4.7) 276,142 (4.9) 288,692 (5.0) 301,499 (5.2)
Other/Missing 1,096,410 (20.5) 1,082,685 (19.6) 1,070,086 (18.9) 1,070,523 (18.6) 1,078,634 (18.4)
Regionb
East 1,224,764 (22.9) 1,271,944 (23.0) 1,315,371 (23.2) 1,345,336 (23.3) 1,274,946 (21.8)
Central 1,430,524 (26.7) 1,474,761 (26.7) 1,507,182 (26.6) 1,540,296 (26.7) 1,580,949 (25.8)
South 1,711,492 (32.0) 1,780,997 (32.2) 1,831,218 (32.3) 1,868,642 (32.4) 2,057,703 (35.1)
West 988,644 (18.4) 1,001,532 (18.1) 1,010,557 (17.8) 1,014,963 (17.6) 1,011,760 (17.3)
Utilization
≥1 hospitalization 386,786 (7.2) 395,168 (7.1) 395,605 (7.0) 392,938 (6.8) 386,633 (6.6) <.0001
Total hospitalizations 607,170 606,716 605,730 597,372 595,454
≥1 outpatient visit 5,352,117 (99.94%) 5,526,148 (99.9%) 5,661,384 (99.9%) 5,766,489 (100.0%) 5,850,789 (99.96%) 0.7651
Total outpatient visits 63,858,249 67,317,179 70,542,593 73,633,963 75,737,270
Median outpatient visits per
patient, (IQR)
6 (3–14) 6 (3–14) 6 (3–14) 7 (3–15) 7 (3–15) <.0001
NOTE. IQR, interquartile range.
aData were analyzed by and presented in calendar years.
bWest: AK, AZ, CA, CO, HI, ID, MT, NM, NV, OR, UT, WA, WY; Central: AR, IA, IL, KS, LA, MN, MO, ND, NE, OK, SD, TX, WI; South: AL,
Washington DC, FL, GA, KY, MS, NC, PR, SC, TN, VA, WV; East: CT, DE, IN, MA, MD, ME, MI, NH, NJ, NY, OH, PA, RI, VT.
ﬁgure 1. Rate and number of CDIs by year.
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196 to 212 CDI episodes per 100,000 person years), compared
to an increase of 2% from 2009 to 2010 (Table 2). This is
particularly notable for hospital-onset CDI, for which the
CDI incidence increased by 11.4% between 2010 and 2011,
compared to a 5.5% increase between 2009 and 2010 (Table 2).
Changes in CDI testing practices offer a plausible explanation.
We found that the number of positive tests increased sig-
niﬁcantly from 2010 to 2011 (16%) and then remained steady.
Speciﬁcally, across calendar years 2009–2013, the percentages
of all CDI episodes that had a positive CDI test were 37.5%
(2009), 36.6% (2010), 41.6% (2011), 42.0% (2012), and 41.0%
(2013), with a single large increase between 2010 and 2011,
when there was a relative percentage increase of 13.7%
(P< .001). We also studied the volume of CDI tests conducted
and test results (Table 3). We found an increase in positive test
rates, as expected, with the nucleic acid ampliﬁcation tests
(NAATs) in both inpatient and outpatient settings, as well as
an increase in the number of tests performed in the outpatient
setting. Overall, there was a decrease in the number of CDI
tests between 2010 and 2012, although the proportion of tests
with positive results increased. The positive test rate then
decreased in 2013, probably as a result of the overall increase in
the number of tests performed. It appears that NAAT con-
version might have added ~1,000 new cases of CDI per year.
Interestingly, the number and proportion of patients (from the
total number of tests) who were suspected of having CDI and
who were started on CDI treatment (eg, metronidazole or oral
vancomycin) prior to the receipt of test results remained
relatively stable (Table 3).
The prevalence of CDI in the inpatient setting, based on
diagnosis and treatment only, and not counting positive tests,
remained steady in the 5-year span of the study period. In
contrast, the prevalence of CDI in the outpatient setting, based
on diagnosis and treatment only, rose 15% from a rate of
78 per 100,000 persons in 2009 to a rate of 90 per 100,000 persons
in 2013, mostly due to the rising number of community-
associated CDIs among the VHA population.
Trends in CDI by Location of Onset and Attribution
We observed some changes in the setting to which CDI were
attributed over the study period. The proportion of CDI
episodes deﬁned as being community-onset was ~64%, while
the proportion of CDI episodes deﬁned as being healthcare-
facility-onset was ~36% (Table 4). Within the community-
onset episodes, the proportion attributed to healthcare facilities,
whether hospital or long-term care facility, decreased from
12.8% of all CDIs in 2009 to 9.1% in 2013. Conversely, the
proportion of community-onset CDI episodes determined to be
community-associated rose during this time period, from
40.9% in 2009 to 48.3% in 2013, a relative change of 18%
(P< .001) (Table 3).
discussion
We conducted a retrospective cohort study to determine the
incidence of CDI among VHA patients receiving care in the
inpatient and outpatient settings. We observed a sharp increase
in CDI episodes in the VHA from 2010 to 2011 that leveled off
in 2012 and 2013 (Figure 1). We believe this could be attrib-
uted to the adoption of the more sensitive NAAT by the VHA
because as the testing density (ie, the number of CDI tests per
visit) remained stable throughout the study period. We also
observed that the proportion of CDI episodes with onset and
acquisition in the community setting rose during this time
period (Figure 1).
Evans et al19 recently published a study of CDI in VHA acute
care facilities, based on self-reported inpatient data from
October 2010 through June 2012. Despite the use of different
methods, we found similar inpatient rates. For instance, in the
table 2. Clostridium difﬁcile Infection (CDI) Episodes by Type and Year
Characteristic 2009 2010 2011 2012 2013
Overall
CDI episodes, No. 10,207 10,754 11,900 12,138 12,143
CDI/100,000 person yearsa 193 196 212 212 209
Inpatient
Cohort size, No. 386,786 395,168 395,605 392,938 386,633
CDIs, No. 5,955 6,166 6,969 6,758 6,745
Hospital-onset CDIs/10,000 patient daysa 6.2 6.5 7.2 7.4 7.4
Prevalence of CDI at admission/1,000 hospitalizationsa 4.9 4.9 5.6 5.5 5.6
CDIs per 1,000 hospital staysa 15.4 15.6 17.6 17.2 17.4
Total positive tests 2,552 2,561 3,252 3,283 3,170
Outpatient
Cohort size, No. 5,352,117 5,526,148 5,661,384 5,766,489 5,883,928
CDIs, No. 4,252 4,588 4,931 5,380 5,398
CDIs per 100,000 populationa 79.4 83 87.1 93.3 91.7
Total positive tests 1,252 1,344 1,664 1,768 1,743
aChanges in these rates from 2009 to 2013 were statistically signiﬁcant (P< .001).
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study by Evans et al, the pooled CDI admission prevalence rate
was 0.66 cases per 100 admissions, whereas ours was 0.55 cases
per 100 admissions (Table 2). Data regarding where CDI onset
occurred and where C. difﬁcile was acquired were also similar.
Of their CDI admissions, Evans et al estimated those
community-onset not-healthcare-facility-associated (CO-not
HCFA) cases to make up ~53%, whereas our numbers suggest
this rate could be as high as 57% (Table 4). Evans et al esti-
mated that the community-onset healthcare facility–associated
(CO-HCFA) cases made up ~21% of total CDI admissions,
whereas our results indicated that this rate was ~15%.
We believe the differences could be attributed to our use of
complete EMR data rather than self-reporting.
We observed a sharp increase in CDI episodes in the VHA
from 2010 to 2011 that leveled off in 2012 and 2013. To
expand upon our results, we conducted a sensitivity analysis
that included CDI rates in 2008. We found similar rates
between 2008 and 2010, suggesting that the surge we detected
in 2010 and 2011 may have been due to exogenous factors.
Additional analyses of CDI rates by age groups over the same
period displayed the same pattern (Figure 2). We believe
that the increase identiﬁed in our study could be attributed
to the wider adoption of NAAT by the VHA. This hypothesis
was supported by Evans et al, who reported that ~32% of
facility clinical laboratories used NAAT in 2010. By 2012, 54%
of VHA clinical laboratories used NAAT. Collectively,
although limited to the VHA population and to data from 2009
to 2013, our ﬁndings suggest that, in the VHA, the dramatic
rise in CDI incidence between 2000 and 20095 has somewhat
abated despite the introduction of signiﬁcantly more sensitive
testing.10 While the yearly number of CDIs continues to
increase, the magnitude of this increase is currently not as
dramatic as it has been in past years. In contrast, onset
locations displayed little change over the study period, and this
variable is not affected by testing methods. Furthermore, we
observed a slight upward trend for outpatient CDI that
table 4. Clostridium difﬁcile Infections by Year, Overall Number, Location of Onset, and Attribution
Characteristic 2009 2010 2011 2012 2013
Total CDIs, No. 10,207 10,754 11,900 12,138 12,143
Healthcare Facility Onset
Healthcare-facility associated, No. 3,790 3,855 4,227 4,138 4,036
% of Total CDIs 37.1 35.8 35.5 34.1 33.2
Community Onset
Healthcare-facility associated, No. 1,305 1,152 1,258 1,115 1,100
% of total CDIs 12.8 10.7 10.6 9.2 9.1
Community associated, No. 4,175 4,727 5,270 5,805 5,863
% of total CDIs 40.9 44.0 44.3 47.8 48.3
Attribution indeterminate, No. 937 1,020 1,145 1,080 1,100
% of total CDIs 9.2 9.5 9.6 8.9 9.1
Total % 100 100 100 100 100
Healthcare-facility–associated CDIs per 100,000 population 95 91 97 91 88
Community-associated CDIs per 100,000 78 85 93 101 100
table 3. Clostridium difﬁcile Infection Tests and Percent of Positive Tests
2009 2010 2011 2012 2013
Inpatient
CDI tests, No. 37,650 33,726 32,854 32,380 33,576
Positive tests, No. 2,552 2,561 3,252 3,283 3,170
Positive tests, % 6.8 7.6 9.9 10.1 9.4
Outpatient
CDI tests, No. 19,376 20,445 21,050 22,323 23,885
Positive tests, No. 1,252 1,344 1,664 1,768 1,743
Positive tests, % 6.5 6.6 7.9 7.9 7.3
Both inpatient and outpatient
CDI tests, No. 57,026 54,171 53,904 54,703 57,461
Positive tests, No. 3,804 3,905 4,916 5,051 4,913
Positive tests, % 6.7 7.2 9.1 9.2 8.6
Treatment given on or before the day of CDI Test
CDI cases, No. 1,536 1,540 1,513 1,538 1,534
% of all CDI tests 2.7 2.8 2.8 2.8 2.7
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deserves continued monitored because this trend could
signiﬁcantly change the VHA’s strategies to reduce the
transmission of CDI.
We looked closely at community-associated CDI cases
using our most recent data (2013, Table 5). Similar to the
ﬁnding of Chitnis et al,21 90% of these cases had outpatient
healthcare exposure in the 12-week period before their
infection. The rate of exposure to antibiotics among CDI
patients was higher in the study by Chitnis et al than in our
study, 56% vs 44%, respectively. This result might be related to
the low number of females in our population (<10%); 67% of the
cohort studied by Chitnis et al were female. However, in our
study, proton pump inhibitor use was almost as frequent as
antibiotics (Table 5).
A number of potential limitations and factors should be
considered when interpreting the results of our study. First, the
speciﬁc deﬁnitions of CDI used in this study have not been
validated through medical chart review. However, the ICD-9
code for C. difﬁcile infection was shown to have sufﬁcient
sensitivity and speciﬁcity.11 The additional use of positive
C. difﬁcile tests and treatment accompanying receipt of a test
was based on clinical grounds and on usual practices employed
in the diagnosis and treatment of patients with CDI at VHA
facilities. Second, we had limited data regarding factors that
could confound our results and explain the stabilization of
CDI rates, such as changes in antibiotic use and infection
control practices. However, the data available to us showed
stable azithromycin and amoxicillin use over this time period.
The VHA did successfully implement a methicillin-resistant
Staphylococcus aureus (MRSA) bundle around the study period
(2007–2010). Jain et al23 found a decline in healthcare-
associated CDI in a limited number of non-ICU patients, with
no signiﬁcant change noted in ICU patients.12 Thus, it does
not appear that these factors contributed to an increase in the
rate of CDI.
The VHA population is predominantly male, with men
accounting for 93% of the inpatient population in 2012. More
notably with regard to CDI risk, 50% of the 2012 inpatient
population was age 65 or over, and 9% of the inpatient
population was over the age of 85; both of these age groups are
at greater risk for CDI. Furthermore, the VHA system employs
its own policies, practices, and guidelines and functions rela-
tively independently of other healthcare systems in the United
States. Thus, our ﬁndings based on a veteran patient popula-
tion cared for within an independent healthcare system may
not be directly translatable to other populations and settings.
However, the incidence rates we report as well as their dis-
tribution based on location of onset and acquisitions appear to
be within the range based on the newly released data from
Emerging Infections Program (EIP) of the Centers for Disease
Control and Prevention.13
table 5. Clinical Characteristics among Patients with Community-Associated Clostridium difﬁcile Infection, 2013
Characteristic No. %
Total 5,863 100
Outpatient health care exposure in the previous 12 weeks 5,292 90
Medication use within 12 weeks before Clostridium difﬁcile infection
Any antibiotics 2,596 44






Any antibiotics but no proton pump inhibitor 1,361 23
H2 receptor antagonist 483 8
Immunosuppressive 244 4
Proton pump inhibitor 2,478 42
Proton pump inhibitor without antibiotics 1,243 21
Proton pump inhibitor with antibiotics 1,235 21
ﬁgure 2. CDI rates by age group and year.
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This is the largest study utilizing EMR data to describe the
evolution of the CDI epidemiology at VHA over several years.
The age demographics of the VHA population highlight the
need for understanding the trends and epidemiology of CDI in
this population. As the VHA continues to adopt more sensitive
testing methods, the epidemiology of CDI in VHA is changing;
however, the major effect of this diagnostic change may
already have occurred. Our results should establish a new base
rate by which to measure the effect of new CDI infection
control measures currently being employed in VHA. Overall,
despite an aging population with greater burden of comor-
bidity, our data show that VHA inpatient CDI rates stabilized
between 2011 and 2013. In contrast, an area of concern is
the noticeable rise in outpatient CDI rates, particularly of
community-onset and/or community-associated cases. More
studies are needed to identify patient groups at high risk
for CDI and to develop effective and cost-efﬁcient policies
and procedures to combat CDI and improve the health of
veterans.
acknowledgments
The authors thank Drs. Clarisse Demont and Christian Felter for their careful
review of the manuscript.
Financial support: This research was supported by an unrestricted research
grant from Sanoﬁ-Pasteur, Lyon, France.
Potential conﬂicts of interest: Dr. Young-Xu reports personal fees from
Sanoﬁ-Pasteur during the study and personal fees from Sanoﬁ-Pasteur outside
the submitted work. Dr. Gerding holds patents for the treatment and pre-
vention of CDI licensed to ViroPharma/Shire. He is a consultant for Merck,
Shire, Cubist, Rebiotix, Sanoﬁ-Pasteur, Pﬁzer, and Actelion, and he holds
research grants from Seres Health, GOJO, the Centers for Disease Control and
Prevention, and the US Department of Veterans Affairs Research Service.
Dr. Dubberke reports grants and personal fees from Sanoﬁ-Pasteur during the
study as well as grants from Microdermis and personal and/or other remu-
nerations from Cubist, Merck, and Rebiotix outside the submitted work.
Dr. Olsen reports grants from Sanoﬁ-Pasteur during the study, as well
as personal fees from Sanoﬁ-Pasteur and Pﬁzer and grants from Cubist
Pharmaceuticals outside the submitted work. Dr. Kelly reports personal fees
outside the submitted work from Astellas, Cubist Pharmaceuticals, Novartis,
MedImmune, Merck and QuantiaMed; grants and personal fees from Sanoﬁ-
Pasteur and Optimer; and grants from CSL-Behring and Merck. In addition,
Dr. Kelly has a patent pending for passive immunotherapy for CDI using IgA.
Dr. Mahé is an employee of Sanoﬁ-Pasteur.
Address correspondence to Yinong Young-Xu, ScD, MA, MS, VAMC
(10A4E), 215 North Main Street, White River Junction, VT, 05009 (Yinong.
Young-Xu@va.gov).
references
1. RupnikM,WilcoxMH, Gerding DN.Clostridium difﬁcile infection:
new developments in epidemiology and pathogenesis. Nat Rev
Microbiol 2009;7:526–536.
2. Koo HL, Garey KW, DuPont HL. Future novel therapeutic agents
for Clostridium difﬁcile infection. Expert Opin Investig Drugs
2010;19:825–836.
3. Kelly CP, LaMont JT. Clostridium difﬁcile—more difﬁcult
than ever. N Engl J Med 2008;359:1932–1940.
4. Dubberke ER, Olsen MA. Burden of Clostridium difﬁcile on the
Healthcare System. Clin Infect Dis 2012;55:S88–S92.
5. Centers for Disease Control and Prevention. QuickStats: rates of
Clostridium difﬁcile infection among hospitalized patients aged
≥65 years, by age group—National Hospital Discharge Survey,
United States, 1996–2009. MMWR Morb Mortal Wkly 2011;
60:1171.
6. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of
Clostridium difﬁcile and serum levels of IgG antibody against
toxin A. N Engl J Med 2000;342:390.
7. McFarland LV,MulliganME, Kwok RY, StammWE. Nosocomial
acquisition of Clostridium difﬁcile infection. N Engl J Med
1989;320:204.
8. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL,
Donskey CJ. Asymptomatic carriers are a potential source for
transmission of epidemic and nonepidemic Clostridium difﬁcile
strains among long-term care facility residents. Clin Infect Dis
2007;45:992.
9. Armbruster S, Goldkind L. A 5-year retrospective review of
experience with Clostridium difﬁcile-associated diarrhea.Mil Med
2012;177:456–459.
10. Jump RL, Olds DM, Jury LA, et al. Specialty care delivery:
bringing infectious disease expertise to the residents of a Veterans
Affairs long-term care facility. J Am Geriatr Soc 2013;61:782–787.
11. Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump
inhibitors are associated with a high rate of serious infections in
veterans with decompensated cirrhosis. Aliment Pharmacol Ther
2012;36:866–874.
12. Huttner B, Jones M, Rubin MA, et al. Double trouble: how big a
problem is redundant anaerobic antibiotic coverage in Veterans
Affairs medical centers? J Antimicrob Chemother 2012;67:1537–1539.
13. McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluor-
oquinolone use and risk factors for Clostridium difﬁcile-associated
disease within a Veterans Administration health care system. Clin
Infect Dis 2007;45:1141–1151.
14. Donskey CJ, Sunkesula VC, Jencson AL, et al. Utility of a com-
mercial PCR assay and a clinical prediction rule for detection of
toxigenic Clostridium difﬁcile in asymptomatic carriers. J Clin
Microbiol 2014;52:315–318.
15. Graber CJ, Madaras-Kelly K, Jones MM, Neuhauser MM,
Goetz MB. Unnecessary antimicrobial use in the context of
Clostridium difﬁcile infection: a call to arms for the Veterans
Affairs Antimicrobial Stewardship Task Force. Infect Control Hosp
Epidemiol 2013;34:651–653.
16. Balbale SN, Johnson S, Burns SP, et al. Community-associated
Clostridium difﬁcile infection among veterans with spinal cord
injury and disorder. Infect Control Hosp Epidemiol 2014;35:577–580.
17. McDonald LC, Coignard B, Dubberke E, Song X, Horan T,
Kutty PK. Recommendations for surveillance of Clostridium
difﬁcile-associated disease. Infect Control Hosp Epidemiol, 28:
140–145.
18. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice
guidelines for Clostridium difﬁcile infection in adults: 2010 update
by the society for healthcare epidemiology of America (SHEA)
and the infectious diseases society of America (IDSA). Infect
Control Hosp Epidemiol 2010;31:431–455.
19. Evans ME. Clostridium difﬁcile infections in Veterans Health
Administration acute care facilities. Infect Control Hosp Epidemiol
2014;35:1037–1042.
1044 infection control & hospital epidemiology september 2015, vol. 36, no. 9
20. Gould CV, Edwards JR, Cohen J, et al. Effect of nucleic acid
ampliﬁcation testing on population-based incidence rates of
Clostridium difﬁcile infection. Clin Infect Dis 2013;57:1304–1307.
21. Chitnis AS, Holzbauer SM, Belﬂower RM, et al. Epidemiology of
community-associated Clostridium difﬁcile infection, 2009
through 2011. JAMA Intern Med 2013;173:1359–1367.
22. Goto M, Ohl ME, Schweizer ML, Perencevich EN. Accuracy of
administrative code data for the surveillance of healthcare-associated
infections: a systematic review and meta-analysis. Clin Infect Dis
2014; Mar 58:688–696.
23. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to
prevent methicillin-resistant Staphylococcus aureus infections.
N Engl J Med 2011;364:1419–1430.
24. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium
difﬁcile infection in the United States. N Engl J Med 2015;372:
825–834.
appendix a. cdi deﬁnitions
Conditions for Identifying CDI episodes
(1) ICD-9-CM diagnosis code for CDI (008.45) during an inpatient hospital stay (discharge diagnosis) or outpatient encounter
(2) Positive test result for C. difﬁcile toxins or toxin genes
(3) Metronidazole or oral vancomycin therapy in the 14 days before or after a CPT-4 code for a C. difﬁcile test (codes 87230, 87324, 87449,
87803, regardless of result)
HCF-onset, HCF-associated CDI
CDIs with onset during a hospitalization or a stay in a long-term or skilled nursing facility
Community-onset, HCF-associated CDI
CDIs with onset in the community (outpatient setting) who had a history of hospitalization or a stay in a long-term or skilled nursing facility in
the 4 weeks prior to onset date
Community-onset, Community-associated CDI
CDIs with onset in the community (outpatient setting) among patients with no history of hospitalization or a stay in a long-term or skilled
nursing facility in the 12 weeks prior to onset date
Indeterminate CDI
CDIs with onset in the community (outpatient setting) among patients with a history of hospitalization or a stay in a long-term or skilled
nursing facility in the 4–12 weeks prior to onset date
cdi among vha patients 1045
